Trends in End-of-Life Care in Women With Metastatic Breast Cancer
A recent analysis of insurance claims data revealed trends in ED visits, ICU visits, hospitalizations, and antineoplastic treatment at the end of life in this population.
Breast Cancer
Managing Oral Mucosal AEs of Adjuvant Endocrine Therapy in Patients With Breast Cancer
A literature review showed strategies for managing oral mucosal AEs in this patient population, including the role of dentists in a multidisciplinary team.
Recent CDC Report Provides Survival Information on Breast Cancer in Men
Late diagnosis of breast cancer significantly impacts survival — and men are generally diagnosed with breast cancer at more advanced stages.
Textured Breast Implants Linked to Higher Breast Cancer Recurrence
The use of textured breast implants for breast reconstruction was associated with increased risk of breast cancer recurrence, warranting further study.
Keytruda Approved for Triple-Negative Breast Cancer
The approval was based on data from the phase 3 KEYNOTE-355 trial that pembrolizumab plus chemotherapy in adults with locally recurrent inoperable or metastatic TNBC, who had not been previously treated with chemotherapy in the metastatic setting.
DBT + Synthetic Mammography Better at Repeat Screening
Cancer detection rate higher for repeat screening with digital breast tomosynthesis + synthetic mammography versus full-field digital mammography.
Selective Use of Nodal Irradiation Recommended for Stage I to III Breast Cancer
Use may be best reserved for those at high risk of recurrence.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Is There An Association Between DCIS and Breast Cancer Mortality?
How effective is surgical treatment for ductal carcinoma in situ (DCIS) at preventing an invasive recurrence of breast cancer? Treatment is intended to significantly lessen the lifetime risk of breast cancer and breast cancer-related mortality, but are patients diagnosed with DCIS still at risk for experiencing poor outcomes? A recent study in JAMA Network Open…
FoundationOne Liquid CDx Approval Expanded to PIK3CA, BRCA, and ALK Alterations
The FDA approved FoundationOne CDx as a companion diagnostic for treatment selection of alpelisib for breast cancer, rucaparib for some gynecologic cancers, and alectinib for lung cancer.
-
Loading...
-
Loading...
Next post in Lung Cancer
